English 中文
English
 
 

About Decheng Capital

Decheng Capital is a leading healthcare investment firm that provides capital to early and growth stage life science companies in China and the U.S. We are a team of investment professionals has complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry. Our domain knowledge, access to innovative technologies and ability to bring proven Western products to China makes them the preferred partner for entrepreneurs, domestic and multinational companies, government agencies and investors. Decheng Capital is poised to capitalize on a historic opportunity in China’s rapidly developing life sciences industry and to deliver superior returns for our investors.

 

News

August 25, 2015
Becton Dickinson Acquires Single-Cell Genomics Startup Cellular Research

August 13, 2015
Roche Acquires GeneWEAVE for up to $425 Million to Strengthen Offerings in Microbiology Diagnostics

May 26, 2015
3SBio Attracts $712 million Hong Kong IPO

February 19, 2015
China's 3SBio Eyes HK Listing Two Years After Going Private

February 11, 2015
Invitae Prices Upsized IPO Above Range at $16

January 9, 2015
Invitae Corporation Files Registration Statement for Proposed Initial Public Offering

October 13, 2014
Invitae Completes $120 Million Series F Financing

July 2, 2014
GeneWeave Attracts $12 Million to Provide Same-Shift Sample-In/Susceptibility-Out Diagnostic Solutions for Multi-Drug-Resistant Organisms

March 6, 2014
Mr. Robert King, Decheng’s Co-Anchor LP, Received the 2014 Arbuckle Award

February 14, 2014
GenapSys Featured on Forbes

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.